יתרות מזומנים בחישוב למניה Traws Pharma Inc (TRAW)

Traws Pharma, Inc. (TRAW) is creating a closed oral therapy system, locking in medical centers through exclusive inhibitor patents. The cash per share metric reflects liquidity dynamics, where the current value is 0.33. The biotech's financial standing is currently tied to external investments and test results. Capital mobility is maintained by outsourcing research to third-party CRO contractors.
פילוחי מדדים מקיפים ואנליטיקה עבור Traws Therapeutics (TRAW)

The metric is calculated by dividing the total volume of liquid assets by the number of shares outstanding. This metric reflects the actual value of cash backing for each share, eliminating distortions from quarterly reporting. For Traws Pharma, Inc. (TRAW), which is debt-free, the value of 0.33 confirms high financial autonomy in the development of antiviral agents. An analysis of the cash per share calculation allows for an assessment of capital stability. The dynamics in this cash per share calculation minimize the risks of deep drawdowns.